替罗非班治疗急性冠脉综合征临床观察

目的观察替罗非班治疗急性冠脉综合征的临床效果和安全性.方法符合急性冠脉综合征(不稳定心绞痛/非Q波心肌梗死)入选标准患者73例,按就诊顺序双盲随机分为受试组(n=37)和对照组(n=36).受试组微量泵持续泵入替罗非班,对照组微量泵持续泵入安慰剂,所有患者均静脉应用普通肝素和口服阿司匹林,疗程均为2.0～4.5 d.观察2组心电图改变、血小板聚集率、主要终点事件(顽固性缺血状态、新近心肌梗死和死亡)及不良反应发生情况.结果与对照组相比,受试组心电图缺血性改变有明显好转(P＜0.05),血小板聚集率明显下降(P＜0.01),主要终点事件有下降趋势,无严重不良反应.结论替罗非班治疗急性冠脉综合征是安全有效的.

Clinical effects of tirofiban on the patients with acute coronary syndrome

Aim:To demonstrate the clinical effects and safety of tirofiban on the patients with acute coronary syndrome (ACS).Methods:73 patients with ACS ( unstable angina/non ST segment elevation myocardial infarction) were randomly divided into tirofiban group ( n =37) which received intravenous tirofiban and control group ( n =36) which received placebo. All patients received intravenous heparin and oral aspirin. The changes of ECG, platelet aggregation rate, the 30 day primary composite end point events (persistent myocardial ischaemic state, new onset myocardial infarction and death) and adverse drug effect were observed. Results:Compared with control group, the patients of tirofiban group had a significant improvement of ECG ( P <0.05), a decrease of platelet aggregation rate ( P <0.01), and reduced tendency of primary composite end point events. There was no significant adverse drug effect in two groups. Concl usion:As a new antiplatelet drug, tirofiban is effective and safe for patients treated with of ACS.